Advancements in clinical developments in neo/adjuvant drug therapy for resectable melanoma: ASCO Annual Congress

Advancements in clinical developments in neo/adjuvant drug therapy for resectable melanoma: ASCO Annual Congress – June 2022

Published:2023-05-17 Issue:2 Volume:99 Page:10-17
ISSN:2313-6294
Container-title:Vestnik dermatologii i venerologii
language:
Short-container-title:Vestnik dermatologii i venerologii

Author:

Andreev Dmitry A.^ORCID,Zavyalov Aleksander A.^ORCID

Abstract

In the structure of the incidence of skin tumors, melanoma accounts for a relatively smaller percentage, but that disease is associated with higher risk of an adverse outcome compared with many other malignancies. The study of innovative clinical developments in drug therapy for resectable melanoma, presented at the American Society of Clinical Oncology Annual Meeting June 2022. The best clinical developments in drug treatment of patients with resectable melanoma were selected for analysis: 1) phase 3 study KEYNOTE-716; 2) PRADO; 3) Neo Trio; 4) SWOG 1512. The presented developments bring extremely promising results for melanoma therapy workflows. The use of cutting-edge anti-cancer therapeutics acting on various molecular targets drastically improves the tumor response as well as straitens the appearance of treatment-related adverse events.

Publisher

Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov

Subject

Infectious Diseases,Dermatology

Link

https://vestnikdv.ru/jour/article/viewFile/1382/pdf

Reference23 articles.

1. Стилиди И.С., Геворкян Т.Г., Шпак А.Г. Совершенствование показателей федерального проекта «Борьба с онкологическими заболеваниями». Вестник Росздравнадзора. 2021;(1):46–53 [Stilidi IS, Gevorkjan TG, Shpak AG. Improvement of indicators of federal project “Fight against oncological diseases”. Vestnik Roszdravnadzora. 2021;(1):46–53. (In Russ.)]

2. Андреев Д.А., Завьялов А.А., Кашурников А.Ю., Добродеев А.Ю. Ключевые критерии оценки качества онкологической помощи: зарубежный опыт. Российский медицинский журнал. 2020;26(6):421–430 [Andreev DA, Zav'jalov AA, Kashurnikov AJu, Dobrodeev AJu. Essential criteria for assessing the quality of cancer care: international experience. Rossijskij medicinskij zhurnal. 2020;26(6):421–430 (In Russ.)]

3. Потекаев Н.Н., Титов К.С., Маркин А.А., Кашурников А.Ю. Эпидемиология меланомы кожи в Российской Федерации и в городе Москве за 10 лет (2008–2018 гг.). Клиническая дерматология и венерология. 2020;19(6):810–816 [Potekaev NN, Titov KS, Markin AA, Kashurnikov AJu. Epidemiology of skin melanoma in the Russian Federation and in the city of Moscow for 10 years (2008–2018). Klinicheskaja dermatologija i venerologija. 2020;19(6):810–816. (In Russ.)]

4. Состояние онкологической помощи населению России в 2019 году. Министерство здравоохранения Российской Федерации, Российский центр информационных технологий и эпидемиологических исследований в области онкологии, Научно-исследовательский онкологический институт им. П.А. Герцена. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: б. и.; 2020. 239 c. [Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2019 godu. (The state of oncological care to the population of Russia in 2019.) Ministry of Health of the Russian Federation, Russian Center for Information Technology and Epidemiological Research in the Field of Oncology, P. A. Herzen Cancer Research Institute. Ed. by A.D. Kaprin, V.V. Starinskij, A.O. Shahzadova. Moscow: s. n.; 2020. 239 p. (In Russ).]

5. A systematic review of worldwide incidence of nonmelanoma skin cancer